|
1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Andrews L: Dietary flavonoids for the
prevention of colorectal cancer. Clin J Oncol Nurs. 17:671–672.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Altobelli E, Lattanzi A, Paduano R,
Varassi G and di Orio F: Colorectal cancer prevention in Europe:
Burden of disease and status of screening programs. Prev Med.
62:132–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sugarbaker PH: Colorectal cancer:
Prevention and management of metastatic disease. Biomed Res Int.
2014:7828902014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu H, Gao G, Jiang L, Guo L, Lin M, Jiao
X, Jia W and Huang J: Decreased expression of miR-218 is associated
with poor prognosis in patients with colorectal cancer. Int J Clin
Exp Pathol. 6:2904–2911. 2013.PubMed/NCBI
|
|
7
|
Sun Z, Zhou N, Han Q, Zhao L, Bai C, Chen
Y, Zhou J and Zhao RC: MicroRNA-197 influences 5-fluorouracil
resistance via thymidylate synthase in colorectal cancer. Clin
Transl Oncol. 17:876–883. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brouquet A and Nordlinger B: Metastatic
colorectal cancer outcome and fatty liver disease. Nat Rev
Gastroenterol Hepatol. 10:266–267. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kuipers EJ, Rösch T and Bretthauer M:
Colorectal cancer screening-optimizing current strategies and new
directions. Nat Rev Clin Oncol. 10:130–142. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
De Angelis PM, Svendsrud DH, Kravik KL and
Stokke T: Cellular response to 5-fluorouracil (5-FU) in
5-FU-resistant colon cancer cell lines during treatment and
recovery. Mol Cancer. 5:202006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng K, Liu W, Liu Y, Jiang C and Qian Q:
MicroRNA-133a suppresses colorectal cancer cell invasion by
targeting Fascin1. Oncol Lett. 9:869–874. 2015.PubMed/NCBI
|
|
14
|
Yuan W, Sui C, Liu Q, Tang W, An H and Ma
J: Up-regulation of microRNA-145 associates with lymph node
metastasis in colorectal cancer. PLoS One. 9:e1020172014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Wang Z, Chen M, Peng L, Wang X,
Ma Q, Ma F and Jiang B: MicroRNA-143 targets MACC1 to inhibit cell
invasion and migration in colorectal cancer. Mol Cancer. 11:232012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
O'Hara SP, Mott JL, Splinter PL, Gores GJ
and LaRusso NF: MicroRNAs: Key modulators of posttranscriptional
gene expression. Gastroenterology. 136:17–25. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Broderick JA and Zamore PD: MicroRNA
therapeutics. Gene Ther. 18:1104–1110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu F, Zhang J, Ji M, Li P, Du Y, Wang H,
Zang S, Ma D, Sun X and Ji C: miR-181b increases drug sensitivity
in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J
Oncol. 45:383–392. 2014.PubMed/NCBI
|
|
23
|
Nagano H, Tomimaru Y, Eguchi H, Hama N,
Wada H, Kawamoto K, Kobayashi S, Mori M and Doki Y: MicroRNA-29a
induces resistance to gemcitabine through the Wnt/β-catenin
signaling pathway in pancreatic cancer cells. Int J Oncol.
43:1066–1072. 2013.PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thomas DM and Zalcberg JR: 5-fluorouracil:
A pharmacological paradigm in the use of cytotoxics. Clin Exp
Pharmacol Physiol. 25:887–895. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Noordhuis P, Holwerda U, Van der Wilt CL,
Van Groeningen CJ, Smid K, Meijer S, Pinedo HM and Peters GJ:
5-Fluorouracil incorporation into RNA and DNA in relation to
thymidylate synthase inhibition of human colorectal cancers. Ann
Oncol. 15:1025–1032. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Coget J, Borrini F, Susman S and Sabourin
JC: Colorectal carcinomas in 2013: The search for powerful
prognostic markers is still on the go! Cancer Biomark. 14:145–150.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li T, Gao F and Zhang XP: miR-203 enhances
chemosensitivity to 5-fluorouracil by targeting thymidylate
synthase in colorectal cancer. Oncol Rep. 33:607–614.
2015.PubMed/NCBI
|
|
29
|
Xu AG, Yu ZJ, Jiang B, Wang XY, Zhong XH,
Liu JH, Lou QY and Gan AH: Colorectal cancer in Guangdong province
of China: A demographic and anatomic survey. World J Gastroenterol.
16:960–965. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ades S: Adjuvant chemotherapy for colon
cancer in the elderly: Moving from evidence to practice. Oncology
(Williston Park). 23:162–167. 2009.PubMed/NCBI
|
|
31
|
McEwan DG, Brunton VG, Baillie GS, Leslie
NR, Houslay MD and Frame MC: Chemoresistant KM12C colon cancer
cells are addicted to low cyclic AMP levels in a phosphodiesterase
4-regulated compartment via effects on phosphoinositide 3-kinase.
Cancer Res. 67:5248–5257. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He Y, Wang J, Wang J, Yung VY, Hsu E, Li
A, Kang Q, Ma J, Han Q, Jin P, et al: MicroRNA-135b regulates
apoptosis and chemoresistance in colorectal cancer by targeting
large tumor suppressor kinase 2. Am J Cancer Res. 5:1382–1395.
2015.PubMed/NCBI
|
|
33
|
Mao Y, Chen H, Lin Y, Xu X, Hu Z, Zhu Y,
Wu J, Xu X, Zheng X and Xie L: microRNA-330 inhibits cell motility
by downregulating Sp1 in prostate cancer cells. Oncol Rep.
30:327–333. 2013.PubMed/NCBI
|
|
34
|
Meng H, Wang K, Chen X, Guan X, Hu L,
Xiong G, Li J and Bai Y: MicroRNA-330-3p functions as an oncogene
in human esophageal cancer by targeting programmed cell death 4. Am
J Cancer Res. 5:1062–1075. 2015.PubMed/NCBI
|
|
35
|
Liu X, Shi H, Liu B, Li J, Liu Y and Yu B:
miR-330-3p controls cell proliferation by targeting early growth
response 2 in non-small-cell lung cancer. Acta Biochim Biophys Sin
(Shanghai). 47:431–440. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Qu S, Yao Y, Shang C, Xue Y, Ma J, Li Z
and Liu Y: MicroRNA-330 is an oncogenic factor in glioblastoma
cells by regulating SH3GL2 gene. PLoS One. 7:e460102012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Heidelberger C, Chaudhuri NK, Danneberg P,
Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E and
Scheiner J: Fluorinated pyrimidines, a new class of
tumour-inhibitory compounds. Nature. 179:663–666. 1957. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu Y, Du F, Zhao Q, Jin J, Ma X and Li H:
Acquisition of 5-fluorouracil resistance induces
epithelial-mesenchymal transitions through the Hedgehog signaling
pathway in HCT-8 colon cancer cells. Oncol Lett. 9:2675–2679.
2015.PubMed/NCBI
|
|
39
|
Lehman NL: Future potential of thymidylate
synthase inhibitors in cancer therapy. Expert Opin Investig Drugs.
11:1775–1787. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Popat S, Matakidou A and Houlston RS:
Thymidylate synthase expression and prognosis in colorectal cancer:
A systematic review and meta-analysis. J Clin Oncol. 22:529–536.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lenz HJ, Hayashi K, Salonga D, Danenberg
KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S,
Leichman LP and Leichman CG: p53 point mutations and thymidylate
synthase messenger RNA levels in disseminated colorectal cancer: An
analysis of response and survival. Clin Cancer Res. 4:1243–1250.
1998.PubMed/NCBI
|
|
42
|
Copur S, Aiba K, Drake JC, Allegra CJ and
Chu E: Thymidylate synthase gene amplification in human colon
cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol.
49:1419–1426. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cho YB, Chung HJ, Lee WY, Choi SH, Kim HC,
Yun SH and Chun HK: Relationship between TYMS and ERCC1 mRNA
expression and in vitro chemosensitivity in colorectal cancer.
Anticancer Res. 31:3843–3849. 2011.PubMed/NCBI
|
